CTABF - Canntab Therapeutics Limited

Other OTC - Other OTC Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 512.37M
Enterprise Value 311.49M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (3Y Monthly) N/A
52-Week Change 3-67.46%
S&P500 52-Week Change 32.49%
52 Week High 31.6400
52 Week Low 30.3500
50-Day Moving Average 30.4226
200-Day Moving Average 30.5219

Share Statistics

Avg Vol (3 month) 31.42k
Avg Vol (10 day) 381
Shares Outstanding 525.31M
Float 17.31M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Apr 30, 2016
Ex-Dividend Date 4Mar 8, 2016
Last Split Factor (new per old) 2200/1
Last Split Date 3Apr 20, 2018

Financial Highlights

Currency in CAD.

Fiscal Year

Fiscal Year Ends May 31, 2018
Most Recent Quarter (mrq)Feb 28, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-87.91%
Return on Equity (ttm)-239.56%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)170.00%
Gross Profit (ttm)26.67k
EBITDA N/A
Net Income Avi to Common (ttm)N/A
Diluted EPS (ttm)N/A
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)N/A
Total Cash Per Share (mrq)N/A
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)11.35
Book Value Per Share (mrq)N/A

Cash Flow Statement

Operating Cash Flow (ttm)N/A
Levered Free Cash Flow (ttm)N/A